The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 9, 2003, Pages 891-905

  Gardner, J D ^a   Gallo Torres, H ^b   Sloan, S ^c   Robinson, M ^d   Miner Jr , P B ^d  

^a Science for Organizations Inc   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ENDOSCOPY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; ESOPHAGITIS; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; POSTPRANDIAL PERIOD; PROTON PUMPS; TREATMENT FAILURE;

EID: 0242351747     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01777.x     Document Type: Article

References (30)

1. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
2. Robinson M. Medical management of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The Esophagus. 3rd edn. Philadelphia: Lippincott Williams & Wilkins. 1999: 447-62.
3. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
4. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 1363-70.
5. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.
6. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
7. Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
8. Gardner JD, Sloan S, Miner PB Jr, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathologic oesophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 955-64.
9. Gardner JD, Sloan S, Miner PB Jr, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 945-53.
10. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
11. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
12. McNeil BJ, Keeler E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975; 293: 211-5.
13. Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
14. Hanley JA, McNeil BJ. The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
15. Gardner JD, Sloan S, Robinson M, Miner PB Jr. Heartburn severity can predict pathologic oesophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 18: 133-40.
16. Motulsky H. Interpreting laboratory tests: introduction to Bayesian thinking. In: Intuitive Biostatistics. New York: Oxford University Press, 1995: 129-39.
17. Hoffrage U, Lindsey S, Hertwig R, Gigerenzer G. Communicating statistical information. Science 2000; 290: 2261-2.
18. Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for detection of gastroesophageal reflux disease. Gastroenterology 1987; 93: 85-90.
19. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 1992; 87: 1102-11.
20. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
21. Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11: 1137-41.
22. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
23. Gardner JD, Ciociola AA, Robinson M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. J Appl Physiol 2002; 92: 427-34.
24. Holloway RH, Bryant W, Dent J. Failure of transient lower oesophageal sphincter relaxation in response to gastric distension in patients with achalasia: evidence for neural mediation of transient lower oesophageal sphincter relaxations. Gut 1989; 30: 762-7.
25. Holloway RH, Koeyan P, Dent J. Provocation of transient lower esophageal sphincter relaxation by meals with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 1034-9.
26. Boulant J, Mathieu S, D'Amato M, Abergel A, Dapoigny M, Bommelaer G. Cholecystokinin in transient lower esophageal sphincter relaxation due to gastric distension in humans. Gut 1997; 40: 575-81.
27. A receptors in transient lower esophageal sphincter relaxation triggered by gastric distension. Am J Gastroenterol 1998; 93: 1823-8.
28. Clave P. Gonzalez A, Moreno A, et al. Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 1998; 115: 597-604.
29. Hirsch DP, Holloway RH, Tytgat GN, Boeckstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998; 115: 1374-80.
30. Zerbib F, Bruley Des Varannes S, Scarpignato C, Leray V, D'Amato M, Roze C. Endogenous cholecystokinin in post-prandial esophageal sphincter function and fundic tone in humans. Am J Physiol 1998; 275: G1266-73.